Novartis (NOVN) Given a CHF 86 Price Target at Credit Suisse Group

Share on StockTwits

Credit Suisse Group set a CHF 86 price target on Novartis (VTX:NOVN) in a research note issued to investors on Friday, October 19th. The firm currently has a neutral rating on the stock.

Several other equities research analysts have also recently issued reports on the company. UBS Group set a CHF 80 target price on Novartis and gave the stock a neutral rating in a report on Thursday, July 19th. Goldman Sachs Group set a CHF 86 target price on Novartis and gave the stock a neutral rating in a report on Friday, June 29th. Jefferies Financial Group set a CHF 100 target price on Novartis and gave the stock a buy rating in a report on Wednesday, July 18th. Kepler Capital Markets set a CHF 89 target price on Novartis and gave the stock a buy rating in a report on Wednesday, July 18th. Finally, JPMorgan Chase & Co. set a CHF 87 target price on Novartis and gave the stock a neutral rating in a report on Tuesday, October 16th. Eleven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of CHF 89.50.

Shares of Novartis stock traded up CHF 0.34 during trading hours on Friday, hitting CHF 78.38. The company’s stock had a trading volume of 11,210,000 shares, compared to its average volume of 5,980,000. Novartis has a 12-month low of CHF 72.45 and a 12-month high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Further Reading: Penny Stocks, Risk and Reward Factors

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.